08/06/2024 3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/31/2024 4:15 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/29/2024 3:23 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024 4:15 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/11/2024 11:59 AM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/02/2024 4:30 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/02/2024 3:30 PM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
|
07/02/2024 3:30 PM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/28/2024 2:13 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/18/2024 4:31 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting) BIOTECHNOLOGY VALUE FUND L P (Reporting) Biotechnology Value Trading Fund OS LP (Reporting) BVF GP HOLDINGS LLC (Reporting) BVF I GP LLC (Reporting) BVF II GP LLC (Reporting) BVF INC/IL (Reporting) BVF PARTNERS L P/IL (Reporting) BVF Partners OS Ltd. (Reporting) LAMPERT MARK N (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/14/2024 3:39 PM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/14/2024 3:34 PM | Olema Pharmaceuticals (Subject) Point72 Asset Management, L.P. (Filed by)
| Form SC 13G | |
06/06/2024 5:49 PM | Logos Global Management LP (Filed by) Olema Pharmaceuticals (Subject)
| Form SC 13D/A | |
06/06/2024 9:02 AM | Logos Opportunities Fund I LP (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/06/2024 9:05 AM | Logos Opportunities Fund II LP (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/04/2024 8:00 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/04/2024 2:09 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/03/2024 1:55 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/31/2024 11:17 AM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024 6:06 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/08/2024 3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/07/2024 4:00 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/06/2024 3:00 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/30/2024 2:25 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024 4:10 PM | Olema Pharmaceuticals (Filer)
| Form DEFA14A | |
04/26/2024 4:15 PM | Olema Pharmaceuticals (Filer)
| Form ARS | |
03/29/2024 4:00 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2024 10:02 AM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/22/2024 3:31 PM | Deep Track Capital, LP (Filed by) Olema Pharmaceuticals (Subject)
| Form SC 13G | |
03/20/2024 4:30 PM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/11/2024 3:31 PM | Olema Pharmaceuticals (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/11/2024 3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/06/2024 4:36 PM | Olema Pharmaceuticals (Issuer) RAPPAPORT ANDREW (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2024 4:30 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 1:26 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/14/2024 11:53 AM | Kynam Capital Management, LP (Filed by) Olema Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/12/2024 4:16 PM | Olema Pharmaceuticals (Filer)
| Form 424B3 | |
02/12/2024 11:21 AM | JANUS HENDERSON GROUP PLC (Filed by) Olema Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/11/2024 11:15 PM | Olema Pharmaceuticals (Filer)
| Form EFFECT | |
02/05/2024 4:30 PM | Bohen Sean (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 4:30 PM | Kovacs Shane William Charles (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
What is Nvidia’s New $1 Trillion SuperProject? (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9285&Placement=NativeDisplay&Source=NativeDisplay) Find out details on these three critical Nvidia partners immediately. |
02/05/2024 4:30 PM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 4:30 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/02/2024 4:00 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/01/2024 2:24 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2024 1:58 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/29/2024 4:25 PM | BlackRock Inc. (Filed by) Olema Pharmaceuticals (Subject)
| Form SC 13G | |
01/29/2024 6:30 AM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/16/2024 6:30 AM | Kovacs Shane William Charles (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2024 8:07 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/08/2024 7:18 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/05/2024 4:25 PM | Olema Pharmaceuticals (Filer)
| Form 424B5 | |
01/05/2024 4:26 PM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/02/2024 4:30 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/18/2023 5:30 PM | Graham G. Walmsley (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/12/2023 4:55 PM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/12/2023 4:55 PM | Kovacs Shane William Charles (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/08/2023 3:19 PM | Asefaw Senai (Reporting) Olema Pharmaceuticals (Issuer) Paradigm BioCapital Advisors GP LLC (Reporting) Paradigm Biocapital Advisors LP (Reporting) Paradigm BioCapital International Fund Ltd. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/07/2023 7:30 PM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 3/A | |
12/07/2023 7:30 PM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/06/2023 6:48 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/05/2023 4:15 PM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/01/2023 4:15 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/30/2023 9:20 AM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023 6:00 PM | Kovacs Shane William Charles (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/22/2023 6:00 PM | Bohen Sean (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/22/2023 6:00 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/22/2023 6:00 PM | Olema Pharmaceuticals (Issuer) Zojwalla Naseem (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/22/2023 6:00 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/22/2023 2:25 PM | Bohen Sean (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023 2:04 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023 2:12 PM | Kovacs Shane William Charles (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023 1:35 PM | Olema Pharmaceuticals (Subject) Zojwalla Naseem (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023 1:42 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023 2:11 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023 2:16 PM | Bohen Sean (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023 1:49 PM | Kovacs Shane William Charles (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023 1:52 PM | Olema Pharmaceuticals (Subject) Zojwalla Naseem (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2023 4:30 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/03/2023 8:39 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/03/2023 3:53 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/02/2023 7:50 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/02/2023 3:46 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/02/2023 3:21 PM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2023 3:49 PM | Myles David C. (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/31/2023 9:38 AM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2023 6:45 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/18/2023 3:46 PM | Olema Pharmaceuticals (Filer)
| Form 8-K/A | |
10/17/2023 3:42 PM | Garland J. Scott (Reporting) Olema Pharmaceuticals (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
10/17/2023 3:43 PM | Garland J. Scott (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/17/2023 6:33 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
What is Nvidia’s New $1 Trillion SuperProject? (Ad) Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9285&Placement=NativeDisplay&Source=NativeDisplay) Find out details on these three critical Nvidia partners immediately. |
10/10/2023 6:17 AM | Olema Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/29/2023 10:05 AM | Harmon Cyrus (Reporting) Olema Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/21/2023 4:12 PM | Asefaw Senai (Reporting) Olema Pharmaceuticals (Issuer) Paradigm BioCapital Advisors GP LLC (Reporting) Paradigm Biocapital Advisors LP (Reporting) Paradigm BioCapital International Fund Ltd. (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
09/14/2023 3:23 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by) Olema Pharmaceuticals (Subject)
| Form SC 13D/A | |
09/14/2023 3:25 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting) BIOTECHNOLOGY VALUE FUND L P (Reporting) Biotechnology Value Trading Fund OS LP (Reporting) BVF GP HOLDINGS LLC (Reporting) BVF I GP LLC (Reporting) BVF II GP LLC (Reporting) BVF INC/IL (Reporting) BVF PARTNERS L P/IL (Reporting) BVF Partners OS Ltd. (Reporting) LAMPERT MARK N (Reporting) Olema Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/14/2023 3:14 PM | Olema Pharmaceuticals (Filer)
| Form D Notice of Exempt Offering of Securities | |
09/13/2023 4:22 PM | Olema Pharmaceuticals (Subject) Paradigm Biocapital Advisors LP (Filed by)
| Form SC 13G/A | |